Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Early Interferon Beta-1b Treatment Thwarts Multiple-Sclerosis Progression: Presented at AAN By Jill Stein SAN DIEGO, C.A. -- April 5, 2006 -- Using interferon beta-1b (Betaseron) therapy in patients with the first clinical symptoms of multiple sclerosis (MS) significantly postpones the development of clinically definite MS, according to the results of the Betaseron in Newly Emerging Multiple Sclerosis for Initial Treatment (BENEFIT) trial. Principal investigator Mark S. Freedman, MD, director, Multiple Sclerosis Research Unit, University of Ottawa, Ottawa, Ontario, Canada, presented the BENEFIT data here on April 5th at the 58th Annual Meeting of the American Academy of Neurology (AAN). "While doctors typically wait years after a first demyelinating event to start treatment, our study provides a strong rationale for the use of early interferon beta-1b therapy," Dr. Freedman said. Dr. Freedman and colleagues from Canada, Europe, and Israel, randomised 487 patients with a first clinically demyelinating event suggestive of MS and typical magnetic resonance imaging (MRI) findings in a 5:3 ratio to treatment to receive either 250 mcg interferon beta-1b given every other day or placebo as a subcutaneous injection. Treatment continued for up to 24 months, unless patients experienced a second attack and were diagnosed with clinically definite MS. Two coprimary endpoints were defined as follows: 1) the time to clinically definite MS, based on a second clinical demyelinating event or an Expanded Disability Status Scale (EDSS) progression of at least 1.5 points, and 2) the time to MS according to McDonald Criteria. The 2 treatment groups were balanced with regard to demographic and clinical characteristics. The mean age of the study population was 30.7 years. After 2 years, 28% of the interferon beta-1b group had developed clinically definite MS versus 45% of placebo-treated patients (P <.0001). Using McDonald criteria, 69% of the interferon beta 1-b group were determined to have developed MS versus 85% of the placebo cohort (P <.00001). Interferon beta-1b prolonged the time to clinically definite MS by 363 days. The treatment effect was most pronounced in patients with clinically less disseminated disease, lower lesion loads, or no enhancing lesions on MRI. Dr. Freedman said that, as part of the BENEFIT trial, patients will be followed prospectively for up to 5 years to verify the benefit of early treatment on long-term outcome. This study was supported by Schering AG. [Presentation title: Betaseron in Newly Emerging Multiple Sclerosis for Initial Treatment (Benefit): Clinical Outcomes. Abstract S02.001] E-mail this page to a friend or colleague! To print, use this version